A preclinical model of mesothelioma demonstrated that concomitant treatment with anti-CTLA-4 and gemcitabine resulted in synergistic anti-tumor effect, while phased administration resulted in no significant difference as compared to gemcitabine alone [123]. Here, CTLA4 is linked to neoplasm.